Amy Axel
Impact in
- Hematology top 1%
- Multiple Myeloma Research and Treatments
- Oncology top 2%
- Peptidase Inhibition and Analysis
- Cancer Cells and Metastasis
- CAR-T cell therapy research
- Cytokine Signaling Pathways and Interactions
Papers in
- Hematology 16
- Multiple Myeloma Research and Treatments 14
- Oncology 15
- Peptidase Inhibition and Analysis 4
- Cytokine Signaling Pathways and Interactions 4
- Cancer Cells and Metastasis 4
- CAR-T cell therapy research 4
- Co-authors
- A. Kate Sasser (13 shared papers)Brett M. Hall (11 shared papers)Nicholas J. Sullivan (3 shared papers)Tatiana M. Oberyszyn (1 shared paper)Farhad Vesuna (1 shared paper)Nilsa C. Ramirez (1 shared paper)Venu Raman (1 shared paper)Niels W.C.J. van de Donk (7 shared papers)
- Journals
- Blood (9 papers)Clinical Cancer Research (2 papers)Clinical Chemistry and Laboratory Medicine (CCLM) (2 papers)Blood Advances (2 papers)Cancer Research (2 papers)
- Partner nations
- United StatesNetherlandsBelgium
In The Last Decade
Amy Axel
28 papers receiving 2.2k citations
Amy Axel's Hit Papers
Peers
Comparison fields: 5 of 89
- Hematology 944
- Oncology 1.4k
- Genetics 313
- Immunology 530
- Physiology 110
Countries citing papers authored by Amy Axel
This map shows the geographic impact of Amy Axel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Axel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Axel more than expected).
Fields of papers citing papers by Amy Axel
This network shows the impact of papers produced by Amy Axel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Axel. The network helps show where Amy Axel may publish in the future.
Co-authors
The 25 scholars most cited alongside Amy Axel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 29 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Interleukin-6 induces an epithelial–mesenchymal transition phenotype in human breast cancer cells Hit paper breakdown → | 2009 | 605 |
| 2 | Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma Hit paper breakdown → | 2016 | 303 |
| 3 | 2016 | 275 | |
| 4 | 2007 | 187 | |
| 5 | 2017 | 160 | |
| 6 | 2021 | 117 | |
| 7 | 2007 | 102 | |
| 8 | 2018 | 85 | |
| 9 | 2016 | 82 | |
| 10 | 2020 | 68 | |
| 11 | 2016 | 58 | |
| 12 | 2012 | 52 | |
| 13 | 2009 | 36 | |
| 14 | 2016 | 29 | |
| 15 | 2016 | 20 | |
| 16 | 2014 | 16 | |
| 17 | 2015 | 16 | |
| 18 | 2016 | 14 | |
| 19 | 2015 | 12 | |
| 20 | PHARMACODYNAMIC RELATIONSHIP BETWEEN NATURAL KILLER CELLS AND DARATUMUMAB EXPOSURE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA | 2016 | 7 |
About Amy Axel
Amy Axel is a scholar working on Hematology, Oncology, Genetics, Radiology, Nuclear Medicine and Imaging and Molecular Biology, having authored 29 papers that have together received 2.3k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (14 papers), Monoclonal and Polyclonal Antibodies Research (10 papers), Chronic Lymphocytic Leukemia Research (9 papers), Peptidase Inhibition and Analysis (4 papers), Protein Degradation and Inhibitors (4 papers), Cytokine Signaling Pathways and Interactions (4 papers), Cancer Cells and Metastasis (4 papers) and CAR-T cell therapy research (4 papers). The work is most often cited by research in Hematology (944 citations), Oncology (1.4k citations), Genetics (313 citations), Immunology (530 citations) and Physiology (110 citations). Amy Axel has collaborated with scholars based in United States, Netherlands and Belgium. Frequent co-authors include A. Kate Sasser, Brett M. Hall, Nicholas J. Sullivan, Tatiana M. Oberyszyn, Farhad Vesuna, Nilsa C. Ramirez, Venu Raman, Niels W.C.J. van de Donk, Henk M. Lokhorst and Adam Studebaker. Their work appears in journals such as Blood, Clinical Cancer Research, Clinical Chemistry and Laboratory Medicine (CCLM), Blood Advances and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.